Last reviewed · How we verify
Sogyeonghwalhyeol-tang
Sogyeonghwalhyeol-tang, marketed by Gachon University Gil Oriental Medical Hospital, holds a unique position in the traditional Korean medicine segment. The drug's key composition patent is set to expire in 2028, providing a period of exclusive market protection. However, the lack of detailed clinical trial results and revenue data poses a significant risk in assessing its long-term market viability and competitive edge.
At a glance
| Generic name | Sogyeonghwalhyeol-tang |
|---|---|
| Also known as | SGHH |
| Sponsor | Gachon University Gil Oriental Medical Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Efficacy and Safety of Herbal Medicine for Treating Work-related Chronic Low Back Pain (PHASE4)
- Evaluation of Efficacy and Safety of Single and Multiple Therapy of Herbal Medicine/Chuna Therapy on Non-specific Chronic Low Back Pain: A Study Protocol for Multicenter, 3-arm, Randomized, Single Blinded, Parallel Group, Incomplete Factorial Design, Pilot Study - (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sogyeonghwalhyeol-tang CI brief — competitive landscape report
- Sogyeonghwalhyeol-tang updates RSS · CI watch RSS
- Gachon University Gil Oriental Medical Hospital portfolio CI